Our pharmaceutical companies are uniquely supported from discovery through development by our vast pharmaceutical research and development enterprise. The companies' pharmaceuticals pipeline is richer than at any point in our history and competitive with the top tier of the industry, distinct in its balance between small molecules and biologics.

The organization is also uniquely positioned in its ability to converge our proprietary pharmaceutical technologies, as well as foster cross-enterprise collaborations with scientists in our device and diagnostics businesses to create innovative technology platforms.

The advantages of our powerful, decentralized structure that allow us to compete with the tenacity of smaller, entrepreneurial companies are especially evident in our R&D organization. Our "many bets" approach provides opportunities for growth by allowing six R&D companies with semi-independent sites to focus on using different approaches and technologies to discover new drugs:

• Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which focuses primarily on small molecules;
• Centocor, our center of excellence in biologics;
• ALZA, our center of excellence for drug delivery technologies;
• Tibotec, our center of excellence for anti-virals;
• 3-Dimensional Pharmaceuticals, offering drug discovery capabilities that enhance our R&D productivity; and
• Scios, enhancing our capabilities in oral protein-based compounds.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) represents the largest segment of Johnson & Johnson pharmaceutical R&D.

J&JPRD applies creative thinking and cutting-edge technologies to develop innovative, high-value, cost effective products that significantly improve the health and lifestyles of people worldwide.

The organization's researchers and physicians discover, evaluate and develop compounds that target unmet medical needs across a broad range of therapeutic areas, including CNS, oncology, and metabolic and reproductive health. The 4,000 J&JPRD employees worldwide include scientists, physicians, nurses, and administrative staff, all dedicated to making a meaningful impact on patients' lives.

A global R&D powerhouse with expertise in small molecules, genomics, bioinformatics, high throughput screening, and structural biology, J&JPRD offers an elegant balance of novel in-house and in-license compounds that target new pathways and are either expected to be first-in-class or best-in-class. The company also employs a seamless, end-to-end process through all R&D phases -- from discovery and evaluation to development and launch. In combination, these two approaches have resulted in a robust portfolio of diverse pharmaceutical products that address public healthcare needs, including access and affordability, in meaningful ways.

While J&JPRD is part of the world's most comprehensive and broadly based manufacturer of health care products, it more closely resembles a network of agile start-up companies -- one backed by a huge pharmaceutical presence that gives scientists freedom to break new ground.